Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells

Immunity. 2012 Mar 23;36(3):477-90. doi: 10.1016/j.immuni.2012.02.008. Epub 2012 Mar 8.

Abstract

B cells perform many immunological functions, including presenting lipid antigen to CD1d-restricted invariant natural killer T (iNKT) cells, known to contribute to maintaining tolerance in autoimmunity. Patients with systemic lupus erythematous (SLE) display dysregulated B cell responses and reduced peripheral iNKT cell frequencies. The significance of these defects and how they relate to SLE pathogenesis remain elusive. We report that B cells are essential for iNKT cell expansion and activation in healthy donors but fail to exert a similar effect in SLE patients. Defective B cell-mediated stimulation of iNKT cells in SLE patients was associated with altered CD1d recycling, a defect recapitulated in B cells from healthy donors after stimulation with interferon-α (IFN-α) and anti-immunoglobulin (Ig). iNKT cell number and function were restored in SLE patients responding to anti-CD20 treatment upon normalization of CD1d expression exclusively in repopulated immature B cells. We propose that healthy B cells are pivotal for iNKT cell homeostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antigen Presentation*
  • Antigens, CD1d / metabolism*
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / pathology
  • Case-Control Studies
  • Cell Differentiation
  • Cell Proliferation
  • Cytokines / biosynthesis
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lipids / immunology*
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Erythematosus, Systemic / pathology
  • Lupus Erythematosus, Systemic / therapy
  • Lymphocyte Activation
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Natural Killer T-Cells / immunology*
  • Natural Killer T-Cells / pathology
  • Rituximab
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD1d
  • CD1D protein, human
  • Cytokines
  • Immunosuppressive Agents
  • Lipids
  • Rituximab